Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Axitinib Significantly Extended Progression?Free Survival Compared With ... - Medical News Today (press release) |
 |
 |
|
Medical News Today (press release) Pfizer today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression?free survival (PFS) [HR=0.665, 95% CI; P<0.0001], |
